非小细胞-话题@MedSci

#非小细胞#

746篇内容 | 6361人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2060055, encodeId=1dd42060055e0, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, objectTitle=帕博利珠单抗在晚期非小细胞肺癌免疫治疗的夺金之路, objectType=article, longId=220767, objectId=af5a220e670b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=af5a220e670b, replyNumber=0, likeNumber=27, createdTime=2022-08-22, rootId=0, userName=lingaifan, userId=2e07307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=af5a220e670b, moduleTitle=帕博利珠单抗在晚期非小细胞肺癌免疫治疗的夺金之路, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=af5a220e670b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2059997, encodeId=0117205999e34, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, objectTitle=Lung Cancer：布加替尼（brigatinib）治疗既往治疗过的ALK+转移性非小细胞肺癌患者的疗效：真实世界研究, objectType=article, longId=213524, objectId=54582135246b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=54582135246b, replyNumber=0, likeNumber=67, createdTime=2022-01-12, rootId=0, userName=lingaifan, userId=2e07307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=54582135246b, moduleTitle=Lung Cancer：布加替尼（brigatinib）治疗既往治疗过的ALK+转移性非小细胞肺癌患者的疗效：真实世界研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=54582135246b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2060127, encodeId=bd81206012e87, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, objectTitle=J Clin Oncol：雷莫芦单抗联合派姆单抗治疗晚期非小细胞肺癌, objectType=article, longId=728627, objectId=e0bce2862724, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e0bce2862724, replyNumber=0, likeNumber=59, createdTime=2022-09-17, rootId=0, userName=lingaifan, userId=2e07307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e0bce2862724, moduleTitle=J Clin Oncol：雷莫芦单抗联合派姆单抗治疗晚期非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e0bce2862724)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2060098, encodeId=582d2060098a9, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, objectTitle=Chin J Cancer Res：韩宝惠教授团队III期研究表明QL1101和贝伐珠单抗治疗非鳞状非小细胞肺癌疗效相当, objectType=article, longId=300931, objectId=f500300931ea, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f500300931ea, replyNumber=0, likeNumber=75, createdTime=2022-04-13, rootId=0, userName=lingaifan, userId=2e07307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f500300931ea, moduleTitle=Chin J Cancer Res：韩宝惠教授团队III期研究表明QL1101和贝伐珠单抗治疗非鳞状非小细胞肺癌疗效相当, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f500300931ea)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2059992, encodeId=33d520599922e, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, objectTitle=J Thorac Oncol: 真实世界中III期非小细胞肺癌（NSCLC）的治疗模式和临床预后：KINDLE国际多中心回顾性研究, objectType=article, longId=213198, objectId=1fee213198a9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1fee213198a9, replyNumber=0, likeNumber=108, createdTime=2022-06-07, rootId=0, userName=lingaifan, userId=2e07307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1fee213198a9, moduleTitle=J Thorac Oncol: 真实世界中III期非小细胞肺癌（NSCLC）的治疗模式和临床预后：KINDLE国际多中心回顾性研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1fee213198a9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2060045, encodeId=3676206004532, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, objectTitle=埃克替尼与安罗替尼治疗晚期非小细胞肺癌疗效比较及对miR-185-5p、miR-204-5p表达水平影响观察, objectType=article, longId=220671, objectId=e6e52206e1f8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e6e52206e1f8, replyNumber=0, likeNumber=0, createdTime=2021-11-24, rootId=0, userName=lingaifan, userId=2e07307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e6e52206e1f8, moduleTitle=埃克替尼与安罗替尼治疗晚期非小细胞肺癌疗效比较及对miR-185-5p、miR-204-5p表达水平影响观察, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e6e52206e1f8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2059995, encodeId=87472059995a7, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, objectTitle=Ann Oncol：纳武利尤单抗（Nivolumab）联合卡铂、紫杉醇和贝伐珠单抗一线治疗晚期非鳞状非小细胞肺癌的疗效和安全性, objectType=article, longId=213326, objectId=17162133260e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=17162133260e, replyNumber=0, likeNumber=87, createdTime=2021-07-22, rootId=0, userName=lingaifan, userId=2e07307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=17162133260e, moduleTitle=Ann Oncol：纳武利尤单抗（Nivolumab）联合卡铂、紫杉醇和贝伐珠单抗一线治疗晚期非鳞状非小细胞肺癌的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=17162133260e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2060093, encodeId=3e25206009317, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, objectTitle=J Immunother Cancer：基线体重指数(BMI)与晚期非小细胞肺癌（NSCLC）一线免疫联合化疗治疗预后的关系, objectType=article, longId=299739, objectId=e4b0299e3991, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e4b0299e3991, replyNumber=0, likeNumber=63, createdTime=2022-12-23, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e4b0299e3991, moduleTitle=J Immunother Cancer：基线体重指数(BMI)与晚期非小细胞肺癌（NSCLC）一线免疫联合化疗治疗预后的关系, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e4b0299e3991)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2060039, encodeId=5e36206003907, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, objectTitle=Clinical Lung Cancer：晚期非鳞状非小细胞肺癌(NSQ-NSCLC)患者化疗后培美曲塞+/-抗VEGF维持的疗效和安全性, objectType=article, longId=219975, objectId=348e2199e529, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=348e2199e529, replyNumber=0, likeNumber=63, createdTime=2022-03-03, rootId=0, userName=lingaifan, userId=2e07307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=348e2199e529, moduleTitle=Clinical Lung Cancer：晚期非鳞状非小细胞肺癌(NSQ-NSCLC)患者化疗后培美曲塞+/-抗VEGF维持的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=348e2199e529)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2060082, encodeId=c7dc20600826a, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, objectTitle=J Immunother Cancer：PD-L1抑制剂atezolizumab（阿替利珠单抗）联合贝伐珠单抗治疗PD-L1高表达的非鳞状非小细胞肺癌（NS-NSCLC）患者的疗效和安全性, objectType=article, longId=295174, objectId=ce4f2951e4a6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ce4f2951e4a6, replyNumber=0, likeNumber=86, createdTime=2022-09-20, rootId=0, userName=lingaifan, userId=2e07307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ce4f2951e4a6, moduleTitle=J Immunother Cancer：PD-L1抑制剂atezolizumab（阿替利珠单抗）联合贝伐珠单抗治疗PD-L1高表达的非鳞状非小细胞肺癌（NS-NSCLC）患者的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ce4f2951e4a6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2060050, encodeId=57872060050be, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, objectTitle=Front Oncol：血糖控制对晚期非小细胞肺癌(NSCLC)伴有糖尿病患者的生存影响, objectType=article, longId=220720, objectId=1b0a220e20cb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1b0a220e20cb, replyNumber=0, likeNumber=64, createdTime=2022-11-03, rootId=0, userName=lingaifan, userId=2e07307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1b0a220e20cb, moduleTitle=Front Oncol：血糖控制对晚期非小细胞肺癌(NSCLC)伴有糖尿病患者的生存影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1b0a220e20cb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2060052, encodeId=4ccd206005210, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, objectTitle=Front Oncol:非小细胞肺癌脑转移的局部与全身治疗作为首次治疗的生存比较, objectType=article, longId=220759, objectId=9414220e5918, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9414220e5918, replyNumber=0, likeNumber=71, createdTime=2022-04-20, rootId=0, userName=lingaifan, userId=2e07307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9414220e5918, moduleTitle=Front Oncol:非小细胞肺癌脑转移的局部与全身治疗作为首次治疗的生存比较, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9414220e5918)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2059981, encodeId=e0f32059981fb, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, objectTitle=ASCO 2021：摘要概览与展望20 |非小细胞肺癌专题研究速递(03), objectType=article, longId=212199, objectId=b4a621219912, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b4a621219912, replyNumber=0, likeNumber=82, createdTime=2022-03-29, rootId=0, userName=lingaifan, userId=2e07307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b4a621219912, moduleTitle=ASCO 2021：摘要概览与展望20 |非小细胞肺癌专题研究速递(03), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b4a621219912)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2060031, encodeId=3eab206003194, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, objectTitle=早期非小细胞肺癌射波刀靶区勾画, objectType=article, longId=218466, objectId=ea8a218466b0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ea8a218466b0, replyNumber=0, likeNumber=60, createdTime=2022-01-30, rootId=0, userName=lingaifan, userId=2e07307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ea8a218466b0, moduleTitle=早期非小细胞肺癌射波刀靶区勾画, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ea8a218466b0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2060073, encodeId=df7e20600e346, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, objectTitle=Thorac Cancer：术后放疗可提高新辅助化疗+术后病理为ypN2的非小细胞肺癌患者的生存：来自SEER数据库倾向评分匹配分析, objectType=article, longId=291956, objectId=2f9f2919568c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2f9f2919568c, replyNumber=0, likeNumber=56, createdTime=2022-06-16, rootId=0, userName=lingaifan, userId=2e07307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2f9f2919568c, moduleTitle=Thorac Cancer：术后放疗可提高新辅助化疗+术后病理为ypN2的非小细胞肺癌患者的生存：来自SEER数据库倾向评分匹配分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2f9f2919568c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2060025, encodeId=07c820600255c, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, objectTitle=Front Oncol：不可切除的III期非小细胞肺癌同期或续贯放化疗后Durvalumab维持治疗的真实世界、多中心、观察性回顾性研究, objectType=article, longId=217894, objectId=d2e921e89470, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d2e921e89470, replyNumber=0, likeNumber=85, createdTime=2022-01-01, rootId=0, userName=lingaifan, userId=2e07307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d2e921e89470, moduleTitle=Front Oncol：不可切除的III期非小细胞肺癌同期或续贯放化疗后Durvalumab维持治疗的真实世界、多中心、观察性回顾性研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d2e921e89470)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2060049, encodeId=e00620600495e, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, objectTitle=核糖核酸注射液联合胸腺五肽对晚期非小细胞肺癌化疗患者免疫功能的影响, objectType=article, longId=220718, objectId=da46220e18d4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=da46220e18d4, replyNumber=0, likeNumber=77, createdTime=2022-01-09, rootId=0, userName=lingaifan, userId=2e07307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=da46220e18d4, moduleTitle=核糖核酸注射液联合胸腺五肽对晚期非小细胞肺癌化疗患者免疫功能的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=da46220e18d4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2060010, encodeId=94c120600103d, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, objectTitle=Cancers：EGFR突变转移性非小细胞肺癌患者二线治疗后的生存情况, objectType=article, longId=215314, objectId=b54d215314e4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b54d215314e4, replyNumber=0, likeNumber=71, createdTime=2022-03-13, rootId=0, userName=lingaifan, userId=2e07307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b54d215314e4, moduleTitle=Cancers：EGFR突变转移性非小细胞肺癌患者二线治疗后的生存情况, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b54d215314e4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2060077, encodeId=17ef20600e7b6, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, objectTitle=Radiology：双能量CT灌注，让影像学冲在非小细胞肺癌评估的最前线！, objectType=article, longId=293831, objectId=6a44293831cf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6a44293831cf, replyNumber=0, likeNumber=66, createdTime=2022-10-08, rootId=0, userName=lingaifan, userId=2e07307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6a44293831cf, moduleTitle=Radiology：双能量CT灌注，让影像学冲在非小细胞肺癌评估的最前线！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6a44293831cf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2060064, encodeId=5249206006405, content=<a href='/topic/show?id=2cc599381bd' target=_blank style='color:#2F92EE;'>#非小细胞#</a>, objectTitle=JCO：来自keynote189的全新分析: Pembrolizumab联合Pemetrexed和Platinum治疗转移性非鳞状非小细胞肺癌的效果, objectType=article, longId=221052, objectId=063622105235, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=063622105235, replyNumber=0, likeNumber=0, createdTime=2022-05-24, rootId=0, userName=lingaifan, userId=2e07307, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=063622105235, moduleTitle=JCO：来自keynote189的全新分析: Pembrolizumab联合Pemetrexed和Platinum治疗转移性非鳞状非小细胞肺癌的效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=063622105235)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

非小细胞

2020-05-29

lingaifan (审核中...)

前往app查看评论内容

#非小细胞#

帕博利珠单抗在晚期非小细胞肺癌免疫治疗的夺金之路

2022-08-22

lingaifan (审核中...)

前往app查看评论内容

#非小细胞#

Lung Cancer：布加替尼（brigatinib）治疗既往治疗过的ALK+转移性非小细胞肺癌患者的疗效：真实世界研究

2022-01-12

lingaifan (审核中...)

前往app查看评论内容

#非小细胞#

J Clin Oncol：雷莫芦单抗联合派姆单抗治疗晚期非小细胞肺癌

2022-09-17

lingaifan (审核中...)

前往app查看评论内容

#非小细胞#

Chin J Cancer Res：韩宝惠教授团队III期研究表明QL1101和贝伐珠单抗治疗非鳞状非小细胞肺癌疗效相当

2022-04-13

lingaifan (审核中...)

前往app查看评论内容

#非小细胞#

J Thorac Oncol: 真实世界中III期非小细胞肺癌（NSCLC）的治疗模式和临床预后：KINDLE国际多中心回顾性研究

2022-06-07

lingaifan (审核中...)

前往app查看评论内容

#非小细胞#

埃克替尼与安罗替尼治疗晚期非小细胞肺癌疗效比较及对miR-185-5p、miR-204-5p表达水平影响观察

2021-11-24

lingaifan (审核中...)

前往app查看评论内容

#非小细胞#

Ann Oncol：纳武利尤单抗（Nivolumab）联合卡铂、紫杉醇和贝伐珠单抗一线治疗晚期非鳞状非小细胞肺癌的疗效和安全性

2021-07-22

hb2008ye (审核中...)

前往app查看评论内容

#非小细胞#

J Immunother Cancer：基线体重指数(BMI)与晚期非小细胞肺癌（NSCLC）一线免疫联合化疗治疗预后的关系

2022-12-23

lingaifan (审核中...)

前往app查看评论内容

#非小细胞#

Clinical Lung Cancer：晚期非鳞状非小细胞肺癌(NSQ-NSCLC)患者化疗后培美曲塞+/-抗VEGF维持的疗效和安全性

2022-03-03

lingaifan (审核中...)

前往app查看评论内容

#非小细胞#

J Immunother Cancer：PD-L1抑制剂atezolizumab（阿替利珠单抗）联合贝伐珠单抗治疗PD-L1高表达的非鳞状非小细胞肺癌（NS-NSCLC）患者的疗效和安全性

2022-09-20

lingaifan (审核中...)

前往app查看评论内容

#非小细胞#

Front Oncol：血糖控制对晚期非小细胞肺癌(NSCLC)伴有糖尿病患者的生存影响

2022-11-03

lingaifan (审核中...)

前往app查看评论内容

#非小细胞#

Front Oncol:非小细胞肺癌脑转移的局部与全身治疗作为首次治疗的生存比较

2022-04-20

lingaifan (审核中...)

前往app查看评论内容

#非小细胞#

ASCO 2021：摘要概览与展望20 |非小细胞肺癌专题研究速递(03)

2022-03-29

lingaifan (审核中...)

前往app查看评论内容

#非小细胞#

早期非小细胞肺癌射波刀靶区勾画

2022-01-30

lingaifan (审核中...)

前往app查看评论内容

#非小细胞#

Thorac Cancer：术后放疗可提高新辅助化疗+术后病理为ypN2的非小细胞肺癌患者的生存：来自SEER数据库倾向评分匹配分析

2022-06-16

lingaifan (审核中...)

前往app查看评论内容

#非小细胞#

Front Oncol：不可切除的III期非小细胞肺癌同期或续贯放化疗后Durvalumab维持治疗的真实世界、多中心、观察性回顾性研究

2022-01-01

lingaifan (审核中...)

前往app查看评论内容

#非小细胞#

核糖核酸注射液联合胸腺五肽对晚期非小细胞肺癌化疗患者免疫功能的影响

2022-01-09

lingaifan (审核中...)

前往app查看评论内容

#非小细胞#

Cancers：EGFR突变转移性非小细胞肺癌患者二线治疗后的生存情况

2022-03-13

lingaifan (审核中...)

前往app查看评论内容

#非小细胞#

Radiology：双能量CT灌注，让影像学冲在非小细胞肺癌评估的最前线！

2022-10-08

lingaifan (审核中...)

前往app查看评论内容

#非小细胞#

JCO：来自keynote189的全新分析: Pembrolizumab联合Pemetrexed和Platinum治疗转移性非鳞状非小细胞肺癌的效果

2022-05-24

科室
- - 订阅+
  - 更多科室
工具
服务